We are an iconic provider of hospital-based healthcare, striving to deliver an exceptional standard of care
We comprise several hospitals, health centres, a nationally accredited education provider and a world-class research institute
We are a nationally accredited, hospital-based Registered Training Organisation - the only one of its kind in Queensland
We are part of a collaborative research institute with The University of Queensland and founding partner of the Translational Research Institute
Trevor Young was diagnosed with acute myeloid leukemia earlier this year and was kind enough to share his cancer journey in the hopes of raising awareness and funds for this disease.
Trevor had been feeling unwell for several weeks but woke on 29 June 2020 feeling extremely ill and went to his GP.
“My doctor took one look at me and told me to go to Mater Private Hospital Brisbane Emergency and ordered pathology testing to be done straight away. I was admitted immediately and later that day I was told I had leukemia,” Trevor said.
“It was an incredibly fast process as I needed to begin chemotherapy treatment the next day, my doctor Jason Butler said this was a very aggressive cancer and without treatment I only had two weeks to live.
“I was in hospital for three and a half weeks with the first round of chemotherapy, then I had a bone marrow biopsy done. Unfortunately, due to the aggressive nature of the cancer I had to come back into hospital for a further six weeks for a second round of chemotherapy.”
This was not Trevor’s first experience with cancer. In May 2019 he was diagnosed with prostate cancer which today only requires low grade monitoring.
“The chemotherapy for the leukaemia was a very aggressive form of treatment, but I am feeling much better now, I still get tired easily and have to rest, but my appetite is back which is really good,” Trevor said.
“I feel I was always someone who appreciated life, but I have learned to appreciate it more now. This experience has made me realise anything can happen. I can’t thank the Mater staff enough; the nurses have been incredible to me while I have been here.”
Trevor will undergo further treatment with a stem cell transplant using donated tissue from his sister in some weeks’ time. In the meantime, he is looking forward to being able to sit outside in the sunshine and see his family.
Clinical Haematologist Dr Jason Butler explains acute myeloid leukaemia (AML) is a type of blood cancer usually arising from the bone marrow. It leads to an inability for the bone marrow to make healthy blood cells as the leukaemia cells or blast cells take over the body.
“Symptoms include tiredness, fatigue, fevers and sweats, bruising, bone pain and weight loss. They may have an infection that won’t get better, however some people have few symptoms,” Dr Butler said.
“Most people have no risk factors, although exposure to chemicals like petroleum, or previous chemotherapy or radiation treatment for another type of cancer can increase the chance of the disease developing and some other bone marrow diseases can turn into AML.
“AML is treated with intensive chemotherapy. Some patients will also receive new targeted treatments depending upon the subtype of AML. Many patients are best treated with a donor (allogeneic) stem cell transplant.”
Dr Butler said about 30-40 per cent of patients will have long term remission, or cure, with treatment. In patients fit enough to undergo treatment, up to 60 per cent will be cured.
“AML is relatively rare. Around three to four people per 100 000 are diagnosed each year. That equals around 900 to 1000 new patients per year. The average age of diagnosis is 65 to 70, but it can be diagnosed at any age including in infants,” Dr Butler said.
“At this stage, we are not aware of any lifestyle factors that appear to cause AML but appropriate protective equipment for workers in industries exposed to chemicals is very important.”
Executive Director of Mater Research Professor Maher Gandhi is part of the National Strategic Action Plan for Blood Cancer, supported by the Blood Cancer Taskforce, leading haematologists, researchers, patients and partners from across the entire Australian blood cancer community.
"When we support and enable access to novel and specialised therapies, we help save the lives of Australians living with blood cancers. It’s a diagnosis that occurs every 31 minutes and it’s time to change the outcomes for those living with this silent disease,” Maher said.
Trevor will continue his treatment at Mater and is looking forward to spending more time with his family plus watching the cricket through the summer months.
Mater Cars for Cancer
Your Mater lottery ticket purchases fund vital resources and expertise across Mater Research, Mater Health and Mater Education - supporting ground breaking medical research and leading patient care services in our community.
It is estimated that in 2019, 144 713 Australians will be diagnosed with cancer and 49 896 people will die from cancer this year. Your support is vital in helping to improve outcomes and provide hope for those affected by this disease.
When you purchase your Mater Cars for Cancer ticket, you are joining the global effort to change the future of cancer diagnosis, treatment and care, whilst providing support to those in your community receiving treatment at Mater, just like Trevor.
07 3163 1524
07 3163 6142
Louise loved flying high as a QANTAS flight attendant but the call to be part of the solution to the current COVID-19 pandemic was too strong for her to ignore.
Stay up-to-date using Mater’s combined Policy and Procedure Library
The Mater Research Publication Recognition Scheme winners have been announced.
Mater has launched a new digital tool to provide virtual care to COVID-19 patients in their own homes, alleviating pressure on stretched hospital and healthcare services.